Navigation Links
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
Date:6/14/2010

According to SDI, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

(Vocus) June 14, 2010 -- According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

Currently, alendronate, sometimes filled as Fosamax but more frequently as the generic equivalent, is the most popular treatment for osteoporosis. In the 12 months ending April 2010, alendronate accounted for almost 24% of drug issuances for the condition.

Generic alendronate is most often dispensed as a once-weekly therapy. SDI found that 49% of new alendronate patients had discontinued the drug 6 months later. Another 3% had switched to another therapy. After 12 months, 61% of new alendronate patients had discontinued therapy.    

The weekly form of Actonel had similar discontinuation rates. Fifty-four percent of patients taking Actonel once a week had discontinued therapy 6 months after starting; 64% had discontinued after 12 months.

The once-a-month version of Actonel fared slightly better after 6 months with only 47% of patients having discontinued therapy. But at 12 months, 63% had discontinued. The oral form of Boniva, also used once a month, had an even higher percentage of patients discontinuing therapy – 57% after 6 months and 70% after 12.

“Drug adherence is an issue that many in the healthcare industry struggle with, including physicians, pharmacies, and payers. If patients choose to discontinue therapy, they may be at a greater risk for progression of their disease or condition,” said SDI Chief Medical Officer Gregory Hess, M.D., M.B.A.. “There are financial ramifications as well. Using drug therapy to treat osteoporosis is less expensive than treating a patient with a broken bone because they didn’t adhere to therapy.”

About SDI:
SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.

###

Read the full story at http://www.prweb.com/releases/2010/SDIosteoporosis/prweb4134214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
2. SDI Reports: Hospital Outpatient Surgical Procedures Increasing, Surgery Centers Growing
3. SDI Reports: Emergency Room Visits Covered by Medicaid Increased 6% in 2009
4. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
5. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
6. SIRIUS XM to Broadcast Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy
7. Spinal cord stimulation may benefit Parkinsons patients
8. Brain MRI in children: Incidental findings yield disclosure dilemmas for doctors, patients
9. Study reveals causes of survival disparities based on insurance among rectal cancer patients
10. Uninsured more likely to die from trauma than patients with insurance, study finds
11. Intervention program helps breast cancer patients live longer after recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: